SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced it has been selected for addition to the
NASDAQ Biotechnology Index® (Nasdaq: NBI), which will become
effective prior to the open of U.S. markets on Monday, December 18, 2017.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on The Nasdaq Stock
Market® that are classified as either biotechnology or
pharmaceutical, according to the Industry Classification Benchmark.
Additional information about the index is available here.
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy
company developing first-in-class, broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. Tocagen is developing its lead investigational
product candidate, Toca 511 & Toca FC, initially for the
treatment of recurrent high-grade glioma (HGG), a disease with
significant unmet medical need. The U.S. Food and Drug
Administration (FDA) has granted Toca 511 & Toca FC
Breakthrough Therapy Designation for the treatment of recurrent HGG
and the European Medicines Agency (EMA) has granted Toca 511 PRIME
(PRIority MEdicines) designation for the treatment of HGG.
View original content with
multimedia:http://www.prnewswire.com/news-releases/tocagen-added-to-nasdaq-biotechnology-index-300571308.html
SOURCE Tocagen Inc.